Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

By Weycker Derek   Taneja Charu   Edelsberg John   Erder M. Haim   Schmitt Frederick A.   Setyawan Juliana   Oster Gerry  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1187-1197

Informa Healthcare

Access to resources Recommend Favorite

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R.   Alva Gus   Meng Xiangyi   Olin Jason T.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite

Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study

By Klinger Tatjana   Ibach Bernd   Schoenknecht Peter   Kamleiter Martin   Silver Gabrielle   Schroeder Johannes   Mielke Ruediger  

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 723-732

Informa Healthcare

Access to resources Recommend Favorite

CCH Phase 3 Open‐Label Study

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 1, 2015-01 ,pp. : 248-258

John Wiley & Sons Inc

Access to resources Recommend Favorite